1. Circulating tumor DNA detection: A potential tool for colorectal cancer management (Review)
   Huizi Li et al, 2018, Oncology Letters CrossRef
2. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
   Matthias Unseld et al, 2018, Clinical Colorectal Cancer CrossRef
3. Texture in the monitoring of regorafenib therapy in patients with colorectal liver metastases
   Iben R Andersen et al, 2019, Acta Radiologica CrossRef
4. THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE
   M. I. Sluzhev et al, 2021, Siberian journal of oncology CrossRef
5. Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
   Matthias Unseld et al, 2020, Journal of Clinical Medicine CrossRef
6. Efficacy and Safety of TACE Combined with Regorafenib versus TACE in the Third-Line Treatment of Colorectal Liver Metastases
   Haohao Lu et al, 2022, Journal of Oncology CrossRef
7. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic colorectal cancer treated with regorafenib
   Iben R Andersen et al, 2019, Acta Radiologica CrossRef
8. ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
   Da Wang et al, 2023, Open Life Sciences CrossRef
9. The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
   Mifanwy Reece et al, 2019, Frontiers in Genetics CrossRef
10. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
    Pieter A. Boonstra et al, 2020, Cancer and Metastasis Reviews CrossRef
11. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
    Ying-Chi Yang et al, 2018, Bioscience Reports CrossRef